Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction

• Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million
  
  
• Prenetics simplifies investment thesis as company focuses on high-growth consumer health brands IM8, CircleDNA, and Europa
  
  
• Prenetics raised its FY2025 outlook to be US$80 – US$100 million from $73 – US$85 million, driven by the growth of IM8
  

CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million¹, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million² and with $117 million pro-forma short term assets³, while maintaining a debt-free balance sheet.

ACT Genomics’ expertise in clinical diagnostics and next-generation sequencing (NGS) is expected to complement Delta’s existing healthcare solutions portfolio, fostering new synergies and growth opportunities in the precision medicine market.

Danny Yeung, CEO and Co-Founder of Prenetics, commented, “This transaction is a testament to the value we have built within ACT Genomics and marks an important milestone for Prenetics. We are incredibly proud of the ACT Genomics team and their contributions. We are confident that under Delta’s stewardship, ACT Genomics will continue to thrive and make significant contributions to the field of genomic medicine.”

Strategic Transformation: Simplified Business Model with Exceptional Growth

The divestment of ACT Genomics marks the successful completion of Prenetics' strategic transformation, addressing previous investor feedback regarding business complexity while positioning the company for accelerated growth in the high-margin consumer health market. The transaction enables Prenetics to simplify its investment thesis, enhance financial flexibility, accelerate growth focus, and optimize resource allocation.